SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation, a genetic diagnostics company, today announced that it filed an action in the U.S. District Court for the Northern District of California against Myriad Genetics, Inc. (NASDAQ: MYGN). By its suit, Invitae seeks a declaration that certain Myriad patents relating to the BRCA1/2 and MUTYH genes are invalid and are not infringed by Invitae.
Help employers find you! Check out all the jobs and post your resume.
